Physician profile
Felix E Roque
NPI 1366506495
$1,806.69
in general payments reported to CMS, 2019-2025
10 companies · $48.02 in 2025
The $48.02 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $109 · 2021: $450 · 2022: $341 · 2023: $389 · 2024: $296 · 2025: $48.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,160.17 | 2021-2025 | Relistor |
| Daiichi Sankyo INC. | $149.11 | 2019 | |
| Scilex Pharmaceuticals INC. | $115.29 | 2019-2022 | |
| Fisher & Paykel Healthcare Limited | $105.00 | 2021 | |
| Fidia Pharma USA INC. | $89.59 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $71.42 | 2021 | |
| Protega Pharmaceutials INC | $63.77 | 2023-2024 | Roxybond |
| Redhill Biopharma INC. | $25.15 | 2020 | |
| Forte Bio-Pharma LLC | $14.50 | 2023 | Prolate, Nalocet |
| Astrazeneca Pharmaceuticals Lp | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Roque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.